CBNPC de stades précoces (I. II. IIIA)

Choice of drugs, combination with targeted therapies, optimal treatment schedules, the management of stage I NSCLC patients and individually-based adjuvant therapeutic strategies are currently being evaluated in clinical trials in which the participation of all investigators is essential.